Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release

Neuroscience

Volumn 162, Issue 4, 2009, Pages 1072-1080

  Guyon, A ^b   Skrzydelski, D ^a   De Giry, I ^b   Rovere C ^b   Conductier, G ^b   Trocello, J M ^a   Dauge V ^a   Kitabgi, P ^a   Rostene W ^a   Nahon, J L ^b   Melik Parsadaniantz S ^a  

^a INSERM   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

CCL2; dopamine neuron; locomotor activity; microdialysis; patch clamp; substantia nigra

Indexed keywords

DOPAMINE; MACROPHAGE DERIVED CHEMOKINE; POTASSIUM ION;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; LOCOMOTION; MALE; METABOLITE; MICRODIALYSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CELL MEMBRANE; CHEMOKINE CCL2; CORPUS STRIATUM; DOPAMINE; ION CHANNEL GATING; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NEURONS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 68049123116     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.05.048     Document Type: Article

References (54)

1. Andjelkovic A.V., and Pachter J.S. Characterization of binding sites for chemokines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem 75 (2000) 1898-1906
2. Bajetto A., Bonavia R., Barbero S., and Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 82 (2002) 1311-1329
3. Banisadr G., Gosselin R., Mechighel P., Kitabgi P., Rostene W., and Mélik Parsadaniantz S. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain. Functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J Comp Neurol 492 (2005) 178-192
4. Banisadr G., Gosselin R., Mechighel P., Kitabgi P., Rostene W., and Mélik Parsadaniantz S. Highly regionalized neuronal expression of MCP-1/CCL2 in rat brain. Evidence for its colocalization with neurotransmitters and neuropeptides. J Comp Neurol 489 (2005) 275-292
5. Banisadr G., Rostene W., Kitabgi P., and Melik Parsadaniantz S. Chemokines and brain functions. Curr Drugs Targets Inflamm Allerg (2005) 387-399
6. Banisadr G., Queraud-Lesaux F., Boutterin M.C., Pelaprat D., Zalc B., Rostene W., Haour F., and Parsadaniantz S.M. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81 (2002) 257-269
7. Biber K., de Jong E.K., van Weering H.R., and Boddeke H.W. Chemokines and their receptors in central nervous system disease. Curr Drug Targets 7 (2006) 29-46
8. + channels mediate inhibition of orexin neurons by glucose. Neuron 50 (2006) 711-722
9. Callewaere C., Banisadr G., Desarmenien M.G., Mechighel P., Kitabgi P., Rostene W.H., and Melik Parsadaniantz S. The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc Natl Acad Sci U S A 103 (2006) 8221-8226
10. Callewaere C., Banisadr G., Rostene W., and Parsadaniantz S.M. Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation. J Mol Endocrinol 38 (2007) 355-363
11. Cartier L., Hartley O., Dubois-Dauphin M., and Krause K.H. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 48 (2005) 16-42
12. Dansereau M.A., Gosselin R.D., Pohl M., Pommier B., Mechighel P., Mauborgne A., Rostene W., Kitabgi P., Beaudet N., Sarret P., and Melik-Parsadaniantz S. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 106 (2008) 757-769
13. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24 (1988) 19-28
14. Gosselin R.D., Dansereau M.A., Pohl M., Kitabgi P., Beaudet N., Sarret P., and Melik Parsadaniantz S. Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem 15 (2008) 2866-2875
15. Gosselin R.D., Valera C., Banisadr G., Mechighel P., Rostene W., Kitabgi P., and Melik Parsadaniantz S. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurons. J Neurochem 95 (2005) 1023-1035
16. Gourmala N.G., Buttini M., Limonta S., Sauter A., and Boddeke H.W. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 74 (1997) 35-44
17. Grillner P., and Mercuri N.B. Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons. Behav Brain Res 130 (2002) 149-169
18. Gu L., Tseng S.C., and Rollins B.J. Monocyte chemoattractant protein-1. Chem Immunol 72 (1999) 7-29
19. Guyon A., Laurent S., Paupardin-Tritsch D., Rossier J., and Eugene D. Incremental conductance levels of GABAA receptors in dopaminergic neurones of the rat substantia nigra pars compacta. J Physiol 516 Pt 3 (1999) 719-737
20. Guyon A., and Nahon J.L. Multiple actions of the chemokine stromal cell-derived factor-1alpha on neuronal activity. J Mol Endocrinol 38 (2007) 365-376
21. Guyon A., Skrzydelsi D., Rovere C., Rostene W., Parsadaniantz S.M., and Nahon J.L. Stromal cell-derived factor-1alpha modulation of the excitability of rat substantia nigra dopaminergic neurones: presynaptic mechanisms. J Neurochem 96 (2006) 1540-1550
22. Guyon A., Skrzydelski D., Rovere C., Apartis E., Rostene W., Kitabgi P., Melik Parsadaniantz S., and Nahon J.L. Stromal-cell-derived factor 1alpha/CXCL12 modulates high-threshold calcium currents in rat substantia nigra. Eur J Neurosci 28 (2008) 862-870
23. + channels. J Neurosci 29 (2009) 2528-2533
24. Hayashi M., Luo Y., Laning J., Strieter R.M., and Dorf M.E. Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J Neuroimmunol 60 (1995) 143-150
25. Hirsch E.C. Glial cells and Parkinson's disease. J Neurol 247 Suppl 2 (2000) II58-II62
26. Huerta C., Alvarez V., Mata I.F., Coto E., Ribacoba R., Martinez C., Blazquez M., Guisasola L.M., Salvador C., Lahoz C.H., and Pena J. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett 370 (2004) 151-154
27. Hunot S., and Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S49-S58 discussion: S58-S60
28. Hurwitz A.A., Lyman W.D., and Berman J.W. Tumor necrosis factor alpha and transforming growth factor beta upregulate astrocyte expression of monocyte chemoattractant protein-1. J Neuroimmunol 57 (1995) 193-198
29. Jeon S.M., Lee K.M., Park E.S., Jeon Y.H., and Cho H.J. Monocyte chemoattractant protein-1 immunoreactivity in sensory ganglia and hindpaw after adjuvant injection. Neuroreport 19 (2008) 183-186
30. Jung H., Toth P.T., White F.A., and Miller R.J. Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem 104 (2008) 254-263
31. Kalkonde Y.V., Morgan W.W., Sigala J., Maffi S.K., Condello C., Kuziel W., Ahuja S.S., and Ahuja S.K. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res 1128 (2007) 1-11
32. Knabl J., Witschi R., Hosl K., Reinold H., Zeilhofer U.B., Ahmadi S., Brockhaus J., Sergejeva M., Hess A., Brune K., Fritschy J.M., Rudolph U., Mohler H., and Zeilhofer H.U. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 451 (2008) 330-334
33. Kolodziej A., Schulz S., Guyon A., Wu D.F., Pfeiffer M., Odemis V., Hollt V., and Stumm R. Tonic activation of CXC chemokine receptor 4 in immature granule cells supports neurogenesis in the adult dentate gyrus. J Neurosci 28 (2008) 4488-4500
34. Limatola C., Giovannelli A., Maggi L., Ragozzino D., Castellani L., Ciotti M.T., Vacca F., Mercanti D., Santoni A., and Eusebi F. SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci 12 (2000) 2497-2504
35. Mahad D.J., and Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15 (2003) 23-32
36. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035 (2004) 104-116
37. Minami M., Katayama T., and Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci 100 (2006) 461-470
38. Nishimura M., Kuno S., Mizuta I., Ohta M., Maruyama H., Kaji R., and Kawakami H. Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov Disord 18 (2003) 953-955
39. Oh S.B., Cho C., and Miller R.J. Electrophysiological analysis of neuronal chemokine receptors. Methods 29 (2003) 335-344
40. Paladini C.A., Iribe Y., and Tepper J.M. GABAA receptor stimulation blocks NMDA-induced bursting of dopaminergic neurons in vitro by decreasing input resistance. Brain Res 832 (1999) 145-151
41. Pattarini R., Smeyne R.J., and Morgan J.I. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 145 (2007) 654-668
42. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego, CA
43. Pucak M.L., and Grace A.A. Effects of haloperidol on the activity and membrane physiology of substantia nigra dopamine neurons recorded in vitro. Brain Res 713 (1996) 44-52
44. Pycock C.J. Turning behaviour in animals. Neuroscience 5 (1980) 461-514
45. Rostene W., Kitabgi P., and Parsadaniantz S.M. Chemokines: a new class of neuromodulator?. Nat Rev Neurosci 8 (2007) 895-903
46. Shintani F., Kanba S., Nakaki T., Nibuya M., Kinoshita N., Suzuki E., Yagi G., Kato R., and Asai M. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 13 (1993) 3574-3581
47. Skrzydelski D., Guyon A., Dauge V., Rovere C., Apartis E., Kitabgi P., Nahon J.L., Rostene W., and Parsadaniantz S.M. The chemokine stromal cell-derived factor-1/CXCL12 activates the nigrostriatal dopamine system. J Neurochem 102 (2007) 1175-1183
48. Song C., Merali Z., and Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 88 (1999) 823-836
49. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96 (2006) 706-718
50. Teismann P., and Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318 (2004) 149-161
51. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., and Przedborski S. The role of glial cells in Parkinson's disease. Curr Opin Neurol 14 (2001) 483-489
52. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., and Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 643 (1994) 40-49
53. Zigmond M.J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease?. Insights from an animal model of Parkinsonism. Neurobiol Dis 4 (1997) 247-253
54. Zoccarato F., Cavallini L., and Alexandre A. The pH-sensitive dye acridine orange as a tool to monitor exocytosis/endocytosis in synaptosomes. J Neurochem 72 (1999) 625-633